French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in ...

New data from Spherix Global Insights uncover how hematologists are defining the “right patient” for gene therapy, balancing promise with practical barriers in sickle cell disease, thalassemia, and ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative ...

Cirrus’ lead program is a novel AAV gene therapy designed to restore IRAK-M, a central regulator of the eye’s immune homeostasis, so as to ...

Universities must do more to provide students with cell and gene therapy manufacturing skills, according to a new study.

Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio ...

Taysha Gene Therapies (NASDAQ:TSHA) jumped ~39% on Thursday after the U.S. FDA granted its Breakthrough Therapy designation ...

While AMT-130 could result in meaningful revenue for ClearPoint, the Huntington's opportunity is relatively modest compared ...

Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last ...

Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA ...

Though unexpected CRLs issued by the FDA have caused ripples in the industry, the agency's ex-chief counsel Becky Wood ...